Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doesn’t mean it can’t open there and dip back down
Open .13, close .19
Thought that was based off the stock price rise?
Haha. Smoked it!!
He also responded to one of my questions and essentially said, more or less: “Our big product opportunities coming up are CNS and Opioids, we don’t have a Cardiovascular product *yet*.”
Thanks James! Hopefully we start seeing a lot more XR sales before long.
Heard that at .03, and .05, and .10, and .12, and .15.
Then we’ll keep hearing more of the same at .20, and .25, and then at .30, .40, .50, on and on.
You’re an absolute joke on this board. Better cover.
Trying to convince yourself now or what
You tried to discourage people from buying ELTP around the .03s and it’s done a 5x in the months since.
Thoughts?
11,250,000
Maybe. That’s an interesting thought.
Elite’s company blurb lately in the PRs is “a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products.” I guess that can apply to a tiny drug market of 1-2 competitors or something like Adderrall, Vyvanse, etc.
Gotta consider too that these products take years(?) to go from formulation development to initial trials to human trials to filing to approval, right? Market size can always change in the interim and the number of competitors is definitely in flux. If the idea for this dopamine agonist was several years old, we were bringing in fewer revenues then. Maybe it was a “let’s keep the lights on, go for the easier singles and doubles” before we tackle the home run-type products? Just speculating.
My guess as well.
Yeah, wondering if it’s just a delay on FDA’s end or if there was actually a CRL. Like Jour said, if CRL, we should know in a couple weeks.
Not a “needle mover” product but still would be nice to stack another piece of good news on the pile.
Don’t worry about him, he’s a clown just like many of the other clowns on this board trying to tell us for years not to believe our “lying eyes.”
Elite is growing and profitable. They’re already expecting to need more facility space. Revenues have gone up for what, 4 years straight? 10 billion in market size we’re about to be playing in? Adderralls on the shortage list and another big partnership starting on Jan 1? Generic Vyvanse about to be filed? Likely a Concerta in trials next? Oxy on file? Kirko squeezing more $$$ out of all our drugs, large and small, by selling them himself?
The clowns used to have somewhat legitimate arguments - they’ll never get approvals, they’ll go bankrupt, yada yada. They don’t anymore. It’s telling how weak they sound now - “uh something doesn’t seem right.” LOL
If there was a hard 15 on the craps table, that’d be the only bet Jammy ever made.
Nice! Always appreciate your relevant pharmacy insight.
Do you happen to see any differences in supply of, or demand for, Vyvanse vs. Concerta vs. Adderralls where you work?
Aye, probably just in the unlucky 10%.
Hopefully we see it on FDA’s site soon and then a PR shortly after.
It’s possible. My guess is just good ole fashioned government delays though.
Nah he/she/it does that all the time, what a clown. Go back and look, I called it ahead of time.
Predictable idiot. Lol
Why’d you reply to yourself for the 2nd time today?
Haha owned
Still watching for our dopamine agonist approval.
Haha. Now reply to yourself and agree with yourself.
This is the way
Doesn’t matter - .15. Shut your mouth and get out.
Haha. Is this an attempt to make something negative out of a +6.76% move up on almost 4 million volume, immediately after a +39.50% move up on Friday on over 5 million volume??
LOL.
Pretty weak and stupid but do what ya gotta do I guess, shortie. That cat has been outta the bag for awhile now.
That’s what I’m getting at. What if you are “first to file” but your application is garbage and gets a CRL a few months down the road for whatever reason. Surely the company who filed next and with a better application and gets approval actually obtains the exclusivity period.
Doesn’t the FDA first have to review all the applications that filed and see whether they get approved or not to ultimately determine who got first to file…?
“The narrative of the company has fundamentally changed.” 100%.
AFAIK, we won’t know about Oxy first to file until either Elite receives the approval letter where it is explicitly stated, or if it becomes known otherwise that a different company has gotten it.
But we both know you were never leaving at .15 to begin with, right? Still assigned here.
Much rather just have Elite be acquired, even if for a slightly lesser price, than roll the dice on a reverse split. These short seller maggots will do all they can to drop the price afterward.
Theoretically, does Elite even need to uplist at all before being acquired?
He did also say buybacks would be on the table after debt was paid off. I do hope your 6-12 months is accurate but wouldn’t surprise me to see it take a little longer than that.
Ya, it sucked there for years starting the reinvention of the company almost near ground zero but now that some money is coming in, they can keep the conveyor belt of formulation > trials > filing > approval > launch going much more consistently.
Likely a dopamine agonist approval next week.
Hopefully Vigabatrin launch soon?
Likely record breaking, or at least still extremely good, financial report in less than a month.
Approaching 2 months since Vyvanse successful trial results so ANDA filing likely in the near future.
Prasco/Burel deal starts in little over 2 months.
Likely antimetabolite approval in 4ish months, while the dopamine agonist likely will have launched in the interim.
Nice string of catalysts in the queue!
$ELTP$ baby
I agree. Don’t want to act like first-to-file is a done deal, just sets us up for disappointment if it doesn’t happen. I hope we are first, though.
It will be another great feather in Elite’s cap in either case.
Kinda silly to see NWBO where it is compared to ELTP where it is, ain’t it?
Almost exact same outstanding share count but vastly different financial picture. Stock prices should be reversed, IMO.